bluebird bio (NASDAQ:BLUE) Rating Increased to Neutral at JPMorgan Chase & Co.

bluebird bio (NASDAQ:BLUE) was upgraded by equities research analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a research report issued to clients and investors on Monday, Marketbeat.com reports.

Several other research firms also recently issued reports on BLUE. Barclays upped their price objective on shares of bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, December 31st. StockNews.com began coverage on shares of bluebird bio in a research note on Friday, December 20th. They set a “sell” rating for the company. Bank of America downgraded bluebird bio from a “buy” rating to a “neutral” rating and cut their target price for the company from $60.00 to $10.00 in a research report on Friday, November 15th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $80.00 price target on shares of bluebird bio in a research report on Friday, November 15th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $44.14.

bluebird bio Price Performance

Shares of BLUE opened at $4.02 on Monday. The company has a 50 day moving average of $7.73 and a two-hundred day moving average of $9.36. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. bluebird bio has a twelve month low of $3.56 and a twelve month high of $38.40. The company has a market cap of $39.08 million, a price-to-earnings ratio of -0.11 and a beta of 0.68.

Institutional Trading of bluebird bio

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets raised its position in bluebird bio by 2,270.2% during the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 355,562 shares during the period. FMR LLC increased its stake in shares of bluebird bio by 8.1% during the third quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock worth $1,289,000 after purchasing an additional 186,903 shares in the last quarter. Barclays PLC lifted its stake in bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 184,605 shares in the last quarter. Geode Capital Management LLC boosted its holdings in bluebird bio by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock worth $2,433,000 after buying an additional 166,771 shares during the last quarter. Finally, Verition Fund Management LLC purchased a new stake in bluebird bio during the 3rd quarter worth approximately $42,000. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.